INSUBCONTINENT EXCLUSIVE:
In the volatile stock market, significant price drops usually alarm investors, but according to Goldman, Hapvida remains an
exception.Goldman Sachs views the 18% drop in Hapvida, a top Brazilian healthcare provider, since May 20 as an ideal buying chance.This
situation has carved out what Goldman describes as an attractive valuation phase for Hapvida.Goldman Sachs Sees Value in Hapvida After 18%
projected for the close of 2025.This assessment relies on the idea that despite short-term earnings instability and membership growth
service integration and price hikes as grounds for their optimism.Such strategies are expected to stabilize and possibly improve financial
outcomes.Purchasing shares now could yield a real internal rate of return of 14%, Goldman projects.This potential gain stands well above the
just about overcoming adversity, but about seizing a moment ripe with potential.For investors, this presents not just a test of nerve but an
opportunity to back a healthcare titan poised for recovery and growth.
